[go: up one dir, main page]

PE20160045A1 - Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados - Google Patents

Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados

Info

Publication number
PE20160045A1
PE20160045A1 PE2015002617A PE2015002617A PE20160045A1 PE 20160045 A1 PE20160045 A1 PE 20160045A1 PE 2015002617 A PE2015002617 A PE 2015002617A PE 2015002617 A PE2015002617 A PE 2015002617A PE 20160045 A1 PE20160045 A1 PE 20160045A1
Authority
PE
Peru
Prior art keywords
prefusion
rsv
polypeptides
soluble
respiratory syncitial
Prior art date
Application number
PE2015002617A
Other languages
English (en)
Inventor
Anders Krarup
Johannes Petrus Maria Langedijk
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of PE20160045A1 publication Critical patent/PE20160045A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/002—Adverse teaching

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Polipetidos F de prefusion del virus sincicial respiratorio (RSV) estables, composiciones inmunogenicas que comprenden dichos polipeptidos y sus uso en la prevencion y/o el tratamiento de una infeccion por RSV. Estos polipeptidos comprenden al menos un epitope que presenta especificidad por la proteina de la conformacion de prefusion F. En ciertas formas de realizacion, los polipeptidos F de prefusion del RSV son solubles. La invencion tambien provee moleculas de acido nucleico que codifican los polipeptidos F de prefusion del RSV de acuerdo con la invencion y vectores que comprenden a dichas moleculas de acido nucleico
PE2015002617A 2013-06-17 2014-06-17 Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados PE20160045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13172256 2013-06-17

Publications (1)

Publication Number Publication Date
PE20160045A1 true PE20160045A1 (es) 2016-02-18

Family

ID=48625910

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002617A PE20160045A1 (es) 2013-06-17 2014-06-17 Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados

Country Status (20)

Country Link
US (1) US10294279B2 (es)
EP (1) EP3010931B1 (es)
JP (1) JP6679475B2 (es)
KR (1) KR102313153B1 (es)
CN (1) CN105408348B (es)
AP (1) AP2015008893A0 (es)
AU (1) AU2014283334B2 (es)
BR (1) BR112015031509B1 (es)
CA (1) CA2914792C (es)
CL (1) CL2015003655A1 (es)
EA (1) EA034653B1 (es)
HK (1) HK1223949A1 (es)
IL (1) IL243053B (es)
MX (1) MX362792B (es)
MY (1) MY171210A (es)
PE (1) PE20160045A1 (es)
PH (1) PH12015502735B1 (es)
SG (1) SG11201510216RA (es)
WO (1) WO2014202570A1 (es)
ZA (1) ZA201509140B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041659T2 (hu) 2013-04-25 2019-05-28 Janssen Vaccines & Prevention Bv Stabilizált oldható pre-fúziós RSV F polipeptidek
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
EP3821906A1 (en) * 2015-07-07 2021-05-19 Janssen Vaccines & Prevention B.V. Vaccine against rsv comprising modified f polypeptide
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
PH12018501962B1 (en) * 2016-04-05 2023-09-08 Janssen Vaccines And Prevention B V Stablizied soluble pre-fusion rsv f proteins
KR102491447B1 (ko) * 2016-04-05 2023-01-20 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2018187325A1 (en) 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3681533A1 (en) * 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
KR102725189B1 (ko) * 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
EP3969044A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
MX2021013111A (es) * 2019-05-20 2021-11-17 Valneva Se Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio.
JP2022546813A (ja) 2019-09-04 2022-11-09 ユニヴァーシティ オブ ワシントン パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
EP4126023A1 (en) 2020-04-02 2023-02-08 Janssen Vaccines & Prevention B.V. Stabilized vaccine compositions
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN115161344A (zh) * 2022-04-26 2022-10-11 北京智飞绿竹生物制药有限公司 一种针对呼吸道合胞病毒感染的疫苗的制备方法
CN120076825A (zh) 2022-09-29 2025-05-30 辉瑞公司 包含rsv f蛋白三聚体的免疫原组合物
CN119371495B (zh) * 2022-09-29 2025-10-21 北京昌平实验室 一种融合前构象的呼吸道合胞病毒重组融合蛋白、其制备方法及用途
WO2024067725A1 (zh) * 2022-09-29 2024-04-04 北京百邑无忧科技发展有限公司 一种融合前构象的呼吸道合胞病毒重组融合蛋白、其制备方法及用途
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
EP4630049A1 (en) 2022-12-11 2025-10-15 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
US20250135006A1 (en) 2023-07-07 2025-05-01 Pfizer Inc. Amphiphilic tlr7/8 adjuvants and uses thereof
CN119462859A (zh) * 2023-08-09 2025-02-18 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、疫苗及其应用
TW202515998A (zh) * 2023-09-15 2025-04-16 美商伊科薩瓦克斯有限公司 病毒蛋白質及奈米結構及其用途
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
CN117736278B (zh) * 2023-12-25 2025-02-07 英诺特（唐山）生物技术有限公司 一种用于检测呼吸道合胞病毒感染的试剂盒及检测方法
CN117586358B (zh) * 2024-01-19 2024-08-13 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025171026A1 (en) * 2024-02-07 2025-08-14 Pioneer Hi-Bred International, Inc. Methods and compositions to reduce undesirable phenotypic characteristics and/or increase durability of insecticidal proteins in plants
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
CN120192386A (zh) * 2025-02-07 2025-06-24 复星安特金(成都)生物制药有限公司 Rsv f蛋白突变体及其应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
CN1244215B (zh) 1996-11-20 2010-11-03 荷兰克鲁塞尔公司 改进的腺病毒载体生产和纯化方法
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
ATE341614T1 (de) 1998-02-17 2006-10-15 Schering Corp Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ATE519854T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
RU2004125283A (ru) 2002-01-18 2005-06-10 Шеринг Акциенгезельшафт (De) Стабилизированные композиции аденовируса
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
JP4495587B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 組換えアデノウイルスベクターおよびその使用
ATE360683T1 (de) 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1585964A4 (en) 2002-08-28 2008-07-16 Introgen Therapeutics Inc CHROMATOGRAPHIC METHODS FOR PURIFYING ADENOVIRUSES
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
DE602005015332D1 (de) 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
DE602006003420D1 (de) 2005-04-11 2008-12-11 Crucell Holland Bv Virusreinigung mit ultrafiltration
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
KR101617895B1 (ko) 2007-12-24 2016-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
AU2009319254B2 (en) 2008-11-03 2015-04-30 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
JP5796011B2 (ja) 2009-06-24 2015-10-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
KR101696002B1 (ko) 2009-06-24 2017-01-13 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
EP3988115A3 (en) 2009-07-15 2022-08-17 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
MX2012004221A (es) 2009-10-15 2012-06-08 Crucell Holland Bv Proceso para purificacion de adenovirus de cultivos de alta densidad celular.
EP2488636B1 (en) 2009-10-15 2014-03-12 Crucell Holland B.V. Method for the purification of adenovirus particles from high cell density cultures
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
US9139642B2 (en) * 2010-07-09 2015-09-22 Crucell Holland B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
JP2014519819A (ja) * 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
PL2825640T3 (pl) 2012-03-12 2016-10-31 Partie rekombinowanych adenowirusów o zmienionych końcach
AP2014007994A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against rsv
JP2013247240A (ja) 2012-05-25 2013-12-09 Gigaphoton Inc レーザ装置
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
LT2970398T (lt) * 2013-03-13 2024-08-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv f baltymai prieš susiliejimą ir jų naudojimas
AU2014255865B2 (en) 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G proteins
EA035861B1 (ru) 2013-04-15 2020-08-21 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
HUE041659T2 (hu) 2013-04-25 2019-05-28 Janssen Vaccines & Prevention Bv Stabilizált oldható pre-fúziós RSV F polipeptidek
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados

Also Published As

Publication number Publication date
CA2914792A1 (en) 2014-12-24
AP2015008893A0 (en) 2015-12-31
AU2014283334A1 (en) 2015-12-17
CA2914792C (en) 2024-02-27
BR112015031509B1 (pt) 2023-05-09
PH12015502735A1 (en) 2016-03-07
US20160176932A1 (en) 2016-06-23
EA034653B1 (ru) 2020-03-03
KR20160021196A (ko) 2016-02-24
PH12015502735B1 (en) 2019-06-14
KR102313153B1 (ko) 2021-10-15
CN105408348B (zh) 2021-07-06
JP6679475B2 (ja) 2020-04-15
HK1223949A1 (zh) 2017-08-11
EP3010931B1 (en) 2018-06-13
MX2015017771A (es) 2016-10-04
SG11201510216RA (en) 2016-01-28
WO2014202570A1 (en) 2014-12-24
MY171210A (en) 2019-10-02
MX362792B (es) 2019-02-13
CN105408348A (zh) 2016-03-16
BR112015031509A2 (pt) 2017-08-29
EA201690031A1 (ru) 2016-07-29
IL243053B (en) 2020-06-30
US10294279B2 (en) 2019-05-21
JP2016522230A (ja) 2016-07-28
NZ714594A (en) 2021-07-30
ZA201509140B (en) 2022-03-30
AU2014283334B2 (en) 2018-10-18
CL2015003655A1 (es) 2016-06-03
EP3010931A1 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
PE20160045A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
CY1121600T1 (el) Σταθεροποιημενα διαλυτα πολυπεπτιδια rsv f προσυντηξης
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
EA201890235A1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201892702A1 (ru) Стабилизированные f-белки rsv до слияния
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
BR112019008781A2 (pt) poxvírus quiméricos sintéticos
MX2018000570A (es) Nuevas isoformas de tripsina y su uso.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
BR112018011085A2 (pt) composições farmacêuticas contendo doravirina, fumarato de tenofovir desoproxila e lamivudina
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX382841B (es) Producto para el cuidado bucal y métodos para uso y fabricación de este.
EA201892157A1 (ru) Фосфаплатиновые жидкие составы
EP4461365A3 (en) Respiratory syncytial virus (rsv) vaccine
EA201991993A1 (ru) Применение фенилкреатина в качестве ноотропного агента
TR201910467T4 (tr) Selektif PYY bileşikleri ve bunların kullanımları.
TH153766A (th) อนุพันธ์ พิเพอริดิโน-ไพริมิดีน สำหรับการรักษาการติดเชื้อไวรัส